Feasibility Report - China's Pharmaceutical Market looks into the current pharmaceutical market conditions in China. The report covers various subjects that are considered to be of concern to the pharmaceutical industry and/or investors in the pharmaceutical (pharma) industry in China.After a waiting period of two years, on October 14th, 2008, the Chinese government released the draft of the healthcare reform plan under the official name, 'Opinions on Deepening Pharmaceutical and Health System Reform (Draft),' for public comments. While this document offers limited details on the roadmap for the future of healthcare, it does provide clear statements on the high-level principles and objectives of China's new healthcare systems. In the coming years, multiple topics discussed in this paper will be significantly influenced by this healthcare reform plan.Report Covers:Chapter 1 focuses on the characteristics of the Traditional Chinese Medicine (TCM) market, while Chapter 2 estimates the growth potential for the Chinese Over The Counter (OTC) market. The medical devices sector is presenting a viable business opportunity for both domestic and multinational companies. Chapter 3 provides an overview of the current market size and trends in this fast-growing industry.Contract Research Organizations (CRO) are developing rapidly in China. Outsourcing to Asia and China is also moving up the value chain, from manufacturing to research and development (R&D). In Chapter 4 we elaborate on the drivers and trends in the CRO sector in China.Contract Manufacturing Organisations (CMO) have been established longer than CROs in China, and with an increased commitment to international standards, Chinese CMOs are securing more outsourcing orders from big pharmaceutical companies. In this Chapter the challenges in this sector, which still shows double-digit growth, are discussed.While China tries to build an innovation-oriented country, R&D activities of domestic pharma players are still in their early days. In Chapter 5, we discuss how multinational pharma companies are actively setting up R&D centres in China and look into the motivation behind such an expansion. The new tax regulations established by the central government, which support the shift in China from the world's factory to an international R&D base, are reviewed in Chapter 6.Sales and marketing compliance is high on the agenda of CEOs of multinational pharma companies. Chapter 7 explains how regulators in Western countries are keeping a close eye on sales and marketing activities overseas in an effort to eradicate illegal behavior; and how China also has its own clear-cut version of anti-bribery and corruption legislation in the pharmaceutical and healthcare sector.Over the last ten years, continual cuts to drug prices have pushed many Chinese domestic companies into the red. Chapter 8 looks back on this trend and evaluates whether the price cuts have had their desired effect.In contrast to the mature pharmaceutical markets in the US and Europe, drug distribution in China is substantially different and faces numerous challenges, which are discussed in Chapter 9. Intellectual Property Protection (IPP) has been a major concern for foreign companies operating in China. Chapter 10 discusses how recent developments, such as the growth in R&D expenditures, the proposed changes in the calculation of monetary penalties for infringement, and improvements in Chinese patent law have influenced the level of confidence of foreign firms in the protection of intellectual property.Consolidation in the Chinese pharmaceutical industry continues, as it is a growing sector for mergers and acquisition (M&A) activity in China. Although the impact of the worldwide financial crisis on M&A activity will most likely extend through out 2009 and perhaps beyond. Chapter 11 provides an overview of transactions in the pharmaceutical, medical devices and healthcare services sector.When investors plan to invest in a Chine

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Feasibility Report - China Pharmaceutical Market
Published on August 2009
Report Summary
Feasibility Report - China's Pharmaceutical Market looks into the current pharmaceutical market conditions in China. The report
covers various subjects that are considered to be of concern to the pharmaceutical industry and/or investors in the pharmaceutical
(pharma) industry in China.
After a waiting period of two years, on October 14th, 2008, the Chinese government released the draft of the healthcare reform plan
under the official name, 'Opinions on Deepening Pharmaceutical and Health System Reform (Draft),' for public comments. While this
document offers limited details on the roadmap for the future of healthcare, it does provide clear statements on the high-level
principles and objectives of China's new healthcare systems. In the coming years, multiple topics discussed in this paper will be
significantly influenced by this healthcare reform plan.
Report Covers:
Chapter 1 focuses on the characteristics of the Traditional Chinese Medicine (TCM) market, while Chapter 2 estimates the growth
potential for the Chinese Over The Counter (OTC) market. The medical devices sector is presenting a viable business opportunity for
both domestic and multinational companies. Chapter 3 provides an overview of the current market size and trends in this fast-growing
industry.
Contract Research Organizations (CRO) are developing rapidly in China. Outsourcing to Asia and China is also moving up the value
chain, from manufacturing to research and development (R&D). In Chapter 4 we elaborate on the drivers and trends in the CRO
sector in China.
Contract Manufacturing Organisations (CMO) have been established longer than CROs in China, and with an increased commitment
to international standards, Chinese CMOs are securing more outsourcing orders from big pharmaceutical companies. In this Chapter
the challenges in this sector, which still shows double-digit growth, are discussed.
While China tries to build an innovation-oriented country, R&D activities of domestic pharma players are still in their early days. In
Chapter 5, we discuss how multinational pharma companies are actively setting up R&D centres in China and look into the motivation
behind such an expansion. The new tax regulations established by the central government, which support the shift in China from the
world's factory to an international R&D base, are reviewed in Chapter 6.
Sales and marketing compliance is high on the agenda of CEOs of multinational pharma companies. Chapter 7 explains how
regulators in Western countries are keeping a close eye on sales and marketing activities overseas in an effort to eradicate illegal
behavior; and how China also has its own clear-cut version of anti-bribery and corruption legislation in the pharmaceutical and
healthcare sector.
Over the last ten years, continual cuts to drug prices have pushed many Chinese domestic companies into the red. Chapter 8 looks
back on this trend and evaluates whether the price cuts have had their desired effect.
In contrast to the mature pharmaceutical markets in the US and Europe, drug distribution in China is substantially different and faces
numerous challenges, which are discussed in Chapter 9. Intellectual Property Protection (IPP) has been a major concern for foreign
companies operating in China. Chapter 10 discusses how recent developments, such as the growth in R&D expenditures, the
proposed changes in the calculation of monetary penalties for infringement, and improvements in Chinese patent law have influenced
Feasibility Report - China Pharmaceutical Market Page 1/4

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
the level of confidence of foreign firms in the protection of intellectual property.
Consolidation in the Chinese pharmaceutical industry continues, as it is a growing sector for mergers and acquisition (M&A) activity in
China. Although the impact of the worldwide financial crisis on M&A activity will most likely extend through out 2009 and perhaps
beyond. Chapter 11 provides an overview of transactions in the pharmaceutical, medical devices and healthcare services sector.
When investors plan to invest in a Chinese domestic pharmaceutical company, they often intend to expand their own product line or
to take their target company public. Consequently, a comprehensive set of accounting standards is required. This is needed to meet
the accounting standards of the investor for consolidation purposes abroad or for public listing in a foreign market. The implications
that investors need to consider are reviewed in Chapter 12.
2 business days delivery.
Table of Content
1. Traditional Chinese Medicine (TCM) Market
2. Over The Counter (OTC) Market in China
3. Medical Devices ' A Market of Opportunities
4. Trends in Contract Research (CRO) and Manufacturing (CMO) Organizations in China
5. Domestic R&D Activities in China
6. New Tax Regulations to Support International R&D Base in China
7. Anti-Bribery And Corruption Legislation in China Pharmaceutical Sector
8. Drug Price Analysis
9. Drug Distribution in China Pharmaceutical Market
10. Intellectual Property Protection in China Pharmaceutical Market
11. Mergers And Acquisition (M&A) activity in China Pharmaceutical Market
12. Capital Markets and Financial Reporting: What To Consider'
13. Conclusion ' Looking Forward
Feasibility Report - China Pharmaceutical Market Page 2/4

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Feasibility Report - China Pharmaceutical Market
Product Formats
Please select the product formats and the quantity you require.
License not available
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Feasibility Report - China Pharmaceutical Market Page 3/4

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Feasibility Report - China Pharmaceutical Market Page 4/4